{
    "address": "Ostermalmstorg 5",
    "city": "Stockholm",
    "country": "SE",
    "currency": "SEK",
    "cusip": "W4300E103",
    "description": "Immunicum AB is a biomedical company, which engages in the development of cancer immunotherapies. The company is headquartered in Stockholm, Stockholm and currently employs 30 full-time employees. The company went IPO on 2013-04-22. The firm develops immunotherapy for therapeutic treatment of cancer and infectious diseases. The firm uses therapeutic vaccines to treat an already existing disease and is thus given to the already sick patients; therapeutic cancer vaccines administered to patients in order to delay or stop tumor cell growth, shrink tumors, prevent relapse, or to kill cancer cells that could not be eliminated with other treatments. The firm has several technology platforms, such as The Combig, Intuvax@, Subcuvax@ and The CD70, among others. The firm has several projects which are related to kidney cancer and liver cancer, among others.",
    "employeeTotal": "30.0",
    "exchange": "NASDAQ OMX NORDIC",
    "finnhubIndustry": "Biotechnology",
    "ggroup": "Pharmaceuticals, Biotechnology & Life Sciences",
    "gind": "Biotechnology",
    "gsector": "Health Care",
    "gsubind": "Biotechnology",
    "ipo": "2013-04-22",
    "isin": "SE0005003654",
    "logo": "https://finnhub.io/api/logo?symbol=IMMU.ST",
    "marketCapitalization": 861.4106,
    "naics": "Scientific Research and Development Services",
    "naicsNationalIndustry": "Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology)",
    "naicsSector": "Professional, Scientific, and Technical Services",
    "naicsSubsector": "Professional, Scientific, and Technical Services",
    "name": "Immunicum AB",
    "phone": "4687328400.0",
    "sedol": "B9FHWC4",
    "shareOutstanding": 166.167166,
    "state": "STOCKHOLM",
    "ticker": "IMMU.ST",
    "weburl": "http://immunicum.se/"
}